INNIO N.V. Ordinary Shares vs Roivant Sciences Ltd. Common Shares — how do they compare? INNIO N.V. Ordinary Shares trades at $16.22 (market cap $13.73B), while Roivant Sciences Ltd. Common Shares trades at $33.62 (market cap $24.99B). The key difference: Roivant Sciences Ltd. Common Shares is the larger of the two by market cap, and Roivant Sciences Ltd. Common Shares is trading nearer its 52-week high, INNIO N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold INNIO N.V. Ordinary Shares for 0 Days and Roivant Sciences Ltd. Common Shares for 3 Days on average.
| INIO | ROIV | |
|---|---|---|
Market Cap | $13.73B | $24.99B |
Volume | 5,012,195 | 4,711,562 |
Sector | Industrials | Health |
52-Week High | $41.13 | $41.81 |
52-Week Low | $16.50 | $16.99 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $15.39B | $21.25B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Roivant Sciences (ROIV) trades at $33.35, down 3.58% on the day amid a bearish technical signal. The stock faces fundamental headwinds with a net loss of $172 million in 2025 and negative cash flow, though recent news highlights pipeline progress including positive Phase 2 data for mosliciguat in PH-ILD. Analyst sentiment remains strongly bullish with a consensus price target of $46.75.
The outlook hinges on clinical execution; upside exists if pipeline assets like LISRAYA launch successfully, but high cash burn and profitability challenges pose significant risks. Near-term price action is pressured, but long-term value depends on converting R&D into commercial success.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
INNIO Group designs, manufactures, and services reciprocating gas engines for distributed power generation under its Jenbacher and Waukesha brands, serving applications from data centers to industrial and grid-stabilization uses.
Read more on INIO →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →